- Contributing to improve quality of life for OUD patients and reduce overdose morbidity through improved access to treatment and treatment support
- Based on the AmorphOX® platform develop new medications reducing the need for cold storage and thereby improve access to medication in areas where controlled storage facilities are sparse
Focus area
Access to healthcare
The focus area's vision: Increase access to healthcare among patients with OUD and mental illness and develop new innovative medications meeting large unmet needs
The opioid epidemic in the US is one of the country’s largest health crises. Covid, along with stigma and treatment boundaries, have escalated the situation to where it is today. Orexo is committed to making a difference for all these people and during the year major steps were taken, paving the way for more patients receiving care and lifesaving medication.
UN Sustainable Development Goals
Accessibility
At least one drug based on the AmorphOX platform that meets the need for improved shelf life and does not require cold storage has reached global markets through partnerships.
Continuous work during the year.
Affordability
More financial vulnerable individuals have access to Orexo’s products.
- 100% of Orexo’s pharmaceutical products are reimbursed and show a growing share in the Medicaid segment.1
- 100% of Orexo’s products have patient assistant programs in place.
1. Annual average increase from base year 2023
- 100% of Orexo’s products have patient assistant programs in place.
Orexo's Zubsolv has the potential to help
6.1* million
people in the US towards an OUD free life
*Number of people suffering from opioid dependence in the US in 2023
